$16.76
2.32% yesterday
Nasdaq, Aug 12, 10:14 pm CET
ISIN
US0008991046
Symbol
ADMA

ADMA Biologics, Inc. Stock price

$16.76
-1.92 10.28% 1M
+0.92 5.81% 6M
-0.39 2.27% YTD
+0.31 1.88% 1Y
+14.39 607.17% 3Y
+13.85 475.95% 5Y
+7.75 86.02% 10Y
+8.21 96.02% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.38 2.32%
ISIN
US0008991046
Symbol
ADMA
Industry

Key metrics

Basic
Market capitalization
$3.9b
Enterprise Value
$3.9b
Net debt
$900.0k
Cash
$71.6m
Shares outstanding
238.5m
Valuation (TTM | estimate)
P/E
19.5 | 26.5
P/S
8.5 | 7.6
EV/Sales
8.5 | 7.6
EV/FCF
43.3
P/B
10.5
Financial Health
Equity Ratio
71.4%
Return on Equity
56.6%
ROCE
33.0%
ROIC
54.1%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$459.4m | $516.5m
EBITDA
$151.0m | $222.7m
EBIT
$150.8m | $190.2m
Net Income
$206.8m | $147.6m
Free Cash Flow
$90.3m
Growth (TTM | estimate)
Revenue
62.2% | 21.1%
EBITDA
701.6% | 59.8%
EBIT
733.1% | 36.8%
Net Income
5,780.5% | -25.3%
Free Cash Flow
467.8%
Margin (TTM | estimate)
Gross
52.6%
EBITDA
32.9% | 43.1%
EBIT
32.8%
Net
45.0% | 28.6%
Free Cash Flow
19.7%
More
EPS
$0.8
FCF per Share
$0.4
Short interest
7.4%
Employees
685
Rev per Employee
$620.0k
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a ADMA Biologics, Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
80%
Hold
20%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
459 459
62% 62%
100%
- Direct Costs 218 218
27% 27%
47%
242 242
117% 117%
53%
- Selling and Administrative Expenses 87 87
37% 37%
19%
- Research and Development Expense 2.19 2.19
24% 24%
0%
151 151
702% 702%
33%
- Depreciation and Amortization 0.22 0.22
70% 70%
0%
EBIT (Operating Income) EBIT 151 151
733% 733%
33%
Net Profit 207 207
5,780% 5,780%
45%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Positive
Seeking Alpha
2 days ago
ADMA's growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output. This should help them with margin expansion beginning in 2026. ADMA also reaffirmed its guidance for over $500 million in 2025 revenues and over $625 million by 2026. ...
Positive
Seeking Alpha
4 days ago
ADMA Biologics experienced a significant stock pullback on Thursday after Q2 results, presenting a potential buying opportunity for investors. The company now operates 10 plasma collection centers and manufactures key products BIVIGAM and ASCENIV, supporting its solid growth outlook. The company recently announced a $500 million stock buyback program and initiated a new manufacturing process th...
Neutral
The Motley Fool
6 days ago
Adma Biologics (ADMA) Q2 Revenue Up 14%
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 685
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today